Patents Represented by Attorney, Agent or Law Firm Valeta Gregg
  • Patent number: 8183014
    Abstract: A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.
    Type: Grant
    Filed: September 12, 2011
    Date of Patent: May 22, 2012
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
  • Patent number: 8158581
    Abstract: A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibits improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, such as an immunoglobulin domain, in particular, the Fc domain of IgG or a heavy chain of IgG. IGF1 variants were shown to have improved ability to increase muscle mass in a subject suffering from muscle atrophy caused by cachexia, immobilization, aging, chronic disease, cancer, hereditary condition, an atrophy-causing agent, and the like. IGF1 variants are also effective in decreasing blood glucose in a subject suffering from diabetes or hyperglycemia.
    Type: Grant
    Filed: September 30, 2010
    Date of Patent: April 17, 2012
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: David J. Glass, George D. Yancopoulos, Thomas J. Daly, Nicholas J. Papadopoulos
  • Patent number: 8148107
    Abstract: A human antibody or antigen-binding fragment of an antibody which specifically binds human nerve growth factor (NGF) with KD of 5 pM or less, as measured by surface plasmon resonance, wherein the antibody or fragment thereof binds human NGF with an affinity of about 2-10-fold higher than the antibody or fragment binds rat and mouse NGF. The antibodies are useful in treating pain, including inflammatory pain, post-operative incision pain, neuropathic pain, fracture pain, osteoporotic fracture pain, post-herpetic neuralgia, osteoarthritis, rheumatoid arthritis, cancer pain, pain resulting from burns, gout joint pain, as well as diseases, such as hepatocellular carcinoma, breast cancer, and liver cirrhosis.
    Type: Grant
    Filed: June 23, 2011
    Date of Patent: April 3, 2012
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt
  • Patent number: 8114394
    Abstract: Methods of treating, inhibiting, or ameliorating gout, including chronic acute (refractory) gout, pseudogout, or drug-induced gout, in a human subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein the incidence of a gout flare is reduced or inhibited.
    Type: Grant
    Filed: September 22, 2010
    Date of Patent: February 14, 2012
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Catherine Vicary, Scott Mellis
  • Patent number: 8105805
    Abstract: An isolated antibody or antibody fragment that binds human interleukin-18 receptor alpha (hIL-18R?), comprising a light chain variable region (LCVR) selected from the group consisting of SEQ ID NO: 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 61, 65, 69, 73, 77, and 81 and/or a heavy chain variable region (HCVR) selected from the group consisting of SEQ ID NO: 3, 7, 11, 15, 19, 23, 27, 31, 35, 39, 43, 47, 51, 55, 59, 63, 67, 71, 75, and 79, or a fragment or sequence modified by an amino acid substitution, deletion or addition thereof.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: January 31, 2012
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Tammy H. Huang, Sean Stevens, Joel H. Martin, Jeanette L. Fairhurst, Kevin J. Pobursky, Margaret Karow, Joan A. Windsor, Warren R. Mikluka
  • Patent number: 8097713
    Abstract: The present invention provides nucleic acid molecules which encode human antibodies or antigen-binding fragments thereof that specifically bind human CD20. Also provided are expression vectors comprising nucleic acid molecules that encode anti-CD20 antibodies, and methods of producing anti-human CD20 antibodies or antigen-binding fragments thereof.
    Type: Grant
    Filed: December 13, 2010
    Date of Patent: January 17, 2012
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Joel H. Martin, Li-Hsien Wang, Sean Stevens, Erin M. Allison
  • Patent number: 8092802
    Abstract: The present invention provides methods for treating one or more diseases or disorders which are improved, inhibited or ameliorated by reducing interleukin-4 (IL-4) activity. The methods of the invention comprise administering to a patient an antibody, or antigen-binding fragment thereof, which specifically binds to a human IL-4 receptor.
    Type: Grant
    Filed: June 23, 2010
    Date of Patent: January 10, 2012
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Marcela Torres, Kevin J. Pobursky, Raymond W. Leidich, Joan A. Windsor, Warren R. Mikulka, Diana M. Ahrens, Ergang Shi, Nicholas J. Papadopoulos
  • Patent number: 8084234
    Abstract: Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal.
    Type: Grant
    Filed: March 1, 2010
    Date of Patent: December 27, 2011
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Nicholas J. Papadopoulos, Samuel Davis, George D. Yancopoulos
  • Patent number: 8080248
    Abstract: The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.
    Type: Grant
    Filed: May 14, 2010
    Date of Patent: December 20, 2011
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Allen Radin, Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
  • Patent number: 8075887
    Abstract: The present invention provides methods for treating one or more diseases or disorders which are improved, inhibited or ameliorated by reducing interleukin-4 (IL-4) activity. The methods of the invention comprise administering to a patient an antibody, or antigen-binding fragment thereof, which specifically binds to a human IL-4 receptor.
    Type: Grant
    Filed: September 10, 2009
    Date of Patent: December 13, 2011
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Joel H. Martin, Tammy T. Huang, Jeanette L. Fairhurst, Nicholas J. Papadopoulos
  • Patent number: 8062640
    Abstract: An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.
    Type: Grant
    Filed: December 15, 2009
    Date of Patent: November 22, 2011
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Mark W. Sleeman, Joel H. Martin, Tammy T Huang, Douglas MacDonald
  • Patent number: 8048418
    Abstract: Disclosed is a therapeutic method for inhibiting development or growth of tumors that are resistant to the blockade of delta-like ligand 4 (Dll4), or vascular endothelial growth factor (VEGF), or to other therapeutic agents, by administering the combination of Dll4 antagonist and VEGF antagonist. The combined administration of these two agents, concurrently or sequentially, exhibits synergistic effects on blood vessel development and growth, thereby more effectively inhibiting the tumor growth than an administration of either agent alone. The Dll4 antagonist can be an anti-Dll4 antibody or antibody fragment capable of inhibiting the binding of Dll4 to a Notch receptor, or a fusion protein comprising the extracellular domain of Dll4 or a soluble Notch receptor, or a fragment thereof, fused to a multimerizing component. The VEGF antagonist can be a VEGF trap, anti-VEGF antibody or antibody fragment capable of inhibiting the binding of VEGF to a VEGF receptor.
    Type: Grant
    Filed: May 4, 2009
    Date of Patent: November 1, 2011
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Irene Noguera-Troise, Gavin Thurston, Nicholas Gale, Eric Smith
  • Patent number: 8043617
    Abstract: A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.
    Type: Grant
    Filed: July 13, 2009
    Date of Patent: October 25, 2011
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
  • Patent number: 8029791
    Abstract: Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal.
    Type: Grant
    Filed: April 14, 2008
    Date of Patent: October 4, 2011
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Nicholas J. Papadopoulos, Samuel Davis, George D. Yancopoulos
  • Patent number: 8003103
    Abstract: An isolated antibody or antibody fragment that binds human interleukin-18 receptor alpha (hIL-18R?), comprising a light chain variable region (LCVR) selected from the group consisting of SEQ ID NO: 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 61, 65, 69, 73, 77, and 81 and/or a heavy chain variable region (HCVR) selected from the group consisting of SEQ ID NO: 3, 7, 11, 15, 19, 23, 27, 31, 35, 39, 43, 47, 51, 55, 59, 63, 67, 71, 75, and 79, or a fragment or sequence modified by an amino acid substitution, deletion or addition thereof.
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: August 23, 2011
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Tammy H. Huang, Sean Stevens, Joel H. Martin, Jeanette L. Fairhurst, Kevin J. Pobursky, Margaret Karow, Joan A. Windsor, Warren R. Mikulka
  • Patent number: 7988967
    Abstract: A human antibody or antigen-binding fragment of an antibody which specifically binds human nerve growth factor (NGF) with KD of 5 pM or less, as measured by surface plasmon resonance, wherein the antibody or fragment thereof binds human NGF with an affinity of about 2-10-fold higher than the antibody or fragment binds rat and mouse NGF. The antibodies are useful in treating pain, including inflammatory pain, post-operative incision pain, neuropathic pain, fracture pain, osteoporotic fracture pain, post-herpetic neuralgia, osteoarthritis, rheumatoid arthritis, cancer pain, pain resulting from burns, gout joint pain, as well as diseases, such as hepatocellular carcinoma, breast cancer, and liver cirrhosis.
    Type: Grant
    Filed: August 8, 2008
    Date of Patent: August 2, 2011
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn MacDonald, Richard Torres, Marc R Morra, Joel H Martin, Joel C Reinhardt
  • Patent number: 7972598
    Abstract: Fusion proteins which bind and inhibit vascular endothelial growth factor (VEGF). The VEGF-binding fusion proteins are therapeutically useful for treating VEGF-associated conditions and diseases, and are specifically designed for local administration to specific organs, tissues, and/or cells.
    Type: Grant
    Filed: November 23, 2009
    Date of Patent: July 5, 2011
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Thomas J. Daly, James P. Fandl, Nicholas J. Papadopoulos
  • Patent number: 7964377
    Abstract: Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal.
    Type: Grant
    Filed: December 15, 2008
    Date of Patent: June 21, 2011
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Nicholas J. Papadopoulos, Samuel Davis, George D. Yancopoulos
  • Patent number: 7927583
    Abstract: The present invention provides a fusion polypeptide capable of binding a cytokine to form a nonfunctional complex. It also provides a nucleic acid sequence encoding the fusion polypeptide and methods of making and uses for the fusion polypeptide.
    Type: Grant
    Filed: July 22, 2008
    Date of Patent: April 19, 2011
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Neil Stahl, George D. Yancopoulos
  • Patent number: 7919593
    Abstract: An isolated human antibody or a fragment of a human antibody which specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The human anti-hDll4 antibody or antibody fragment binds hDll4 with an affinity of ?500 pM, as measured by surface plasmon resonance.
    Type: Grant
    Filed: December 14, 2007
    Date of Patent: April 5, 2011
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Nicholas J. Papadopoulos, Joel H. Martin, Eric Smith, Irene Noguera-Troise, Gavin Thurston